On initiation or discontinuation of guselkumab in patients who're getting concomitant CYP450 substrates, significantly Individuals with a narrow therapeutic index, consider monitoring for therapeutic effect. Repotrectinib is usually a CYP3A4 inducer. Stay away from coadministration with CYP3A